Nagai Y, et al. - The authors conducted this prospective, 4-week, single-center, randomized, open-label, parallel-group, treat-to-target study to develop an algorithm for safe and effective switching from basal insulin to once-daily insulin degludec/insulin aspart (IDegAsp) in patients with inadequately controlled type 2 diabetes. Based on fasting plasma glucose data, the IDegAsp dose could be up-titrated by 60% after switching from basal insulin. However, monitoring of postprandial glucose needed to be considered before further up-titration of IDegAsp.